[123I]Iodometomidate Imaging in Adrenocortical Carcinoma

Kreißl, Michael C.; Schirbel, Andreas; Fassnacht, Martin; Haenscheid, Heribert; Verburg, Frederik A.; Böck, Stefanie; Saeger, Wolfgang; Knoedler, Pascal; Reiners, Christoph; Buck, Andreas K.; Allolio, Bruno; Hahner, Stefanie

doi:10.1210/jc.2012-3261

Cited by 43 publications

(19 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Imaging with metomidate labelled with 123 I (iodometomidate, [ 123 I]IMTO) can identify adrenocortical lesions with high specificity but is unable to differentiate benign from malignant lesions. In addition, retention of [ 123 I]IMTO in metastatic lesions can identify patients suitable for specific, targeted radioactive treatment. When available, [ 123 I]IMTO imaging might help to detect distant metastasis before surgery as well as recurrences, as it is an adrenocortical specific tracer.…”

Section: Preoperative Assessment Before Adrenalectomy For Suspected Accmentioning

confidence: 99%

European Society of Endocrine Surgeons (ESES) and European Network for the Study of Adrenal Tumours (ENSAT) recommendations for the surgical management of adrenocortical carcinoma

Gaujoux

Mihai

Ensat

2017

British Journal of Surgery

163

133

View full text Add to dashboard Cite

Background: Radical surgery provides the best chance of cure for adrenocortical carcinoma (ACC), but perioperative surgical care for these patients is yet to be standardized. Methods: A working group appointed jointly by ENSAT and ESES used Delphi methodology to produce evidence-based recommendations for the perioperative surgical care of patients with ACC. Papers were retrieved from electronic databases. Evidence and recommendations were classified according to the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) system, and were discussed until consensus was reached within the group. Results: Twenty-five recommendations for the perioperative surgical care of patients with ACC were formulated. The quality of evidence is low owing to the rarity of the disease and the lack of prospective surgical trials. Multi-institutional prospective cohort studies and prospective RCTs are urgently needed and should be strongly encouraged. Conclusion: The present evidence-based recommendations provide comprehensive advice on the optimal perioperative care for patients undergoing surgery for ACC.

show abstract

Section: Preoperative Assessment Before Adrenalectomy For Suspected Accmentioning

confidence: 99%

European Society of Endocrine Surgeons (ESES) and European Network for the Study of Adrenal Tumours (ENSAT) recommendations for the surgical management of adrenocortical carcinoma

Gaujoux

Mihai

Ensat

2017

British Journal of Surgery

163

133

View full text Add to dashboard Cite

show abstract

“…They did, however, highlight the validity of molecular imaging targeted to CYP11B1 and B2 to distinguish adrenocortical from non-adrenocortical tissue. Subsequent efforts focused on radiolabeling metomidate with isotopes of iodine, to provide more stable ligands with a longer half-life (permitting longer imaging times and clearance of the tracer to other sites away from the adrenals): 123 I-iodometomidate for SPECT imaging; 131 I-iodometomidate as a potential therapeutic radiopharmaceutical agent for treating ACC [48,49,50]; and possibly 124 I-iodometomidate as a PET tracer (although work with this remains pre-clinical) [48,49,50,51]. …”

Section: 123/124/131i-iodometomidate Imaging In Adrenal Diseasementioning

confidence: 99%

“…Hahner and colleagues have specifically evaluated 123 I-iodometomidate imaging in 58 patients with histologically-confirmed adrenocortical carcinoma, using the same methodology described previously [50,59]. 123 I-iodometomidate detected both primary and metastatic ACC.…”

Section: 123/131i-iodometomidate Imaging In Adrenocortical Carcinomentioning

confidence: 99%

Targeted Molecular Imaging in Adrenal Disease—An Emerging Role for Metomidate PET-CT

et al. 2016

View full text Add to dashboard Cite

Adrenal lesions present a significant diagnostic burden for both radiologists and endocrinologists, especially with the increasing number of adrenal ‘incidentalomas’ detected on modern computed tomography (CT) or magnetic resonance imaging (MRI). A key objective is the reliable distinction of benign disease from either primary adrenal malignancy (e.g., adrenocortical carcinoma or malignant forms of pheochromocytoma/paraganglioma (PPGL)) or metastases (e.g., bronchial, renal). Benign lesions may still be associated with adverse sequelae through autonomous hormone hypersecretion (e.g., primary aldosteronism, Cushing’s syndrome, phaeochromocytoma). Here, identifying a causative lesion, or lateralising the disease to a single adrenal gland, is key to effective management, as unilateral adrenalectomy may offer the potential for curing conditions that are typically associated with significant excess morbidity and mortality. This review considers the evolving role of positron emission tomography (PET) imaging in addressing the limitations of traditional cross-sectional imaging and adjunctive techniques, such as venous sampling, in the management of adrenal disorders. We review the development of targeted molecular imaging to the adrenocortical enzymes CYP11B1 and CYP11B2 with different radiolabeled metomidate compounds. Particular consideration is given to iodo-metomidate PET tracers for the diagnosis and management of adrenocortical carcinoma, and the increasingly recognized utility of 11C-metomidate PET-CT in primary aldosteronism.

show abstract

“…123 I-metomidate was also evaluated in a prospective study of 58 patients with metastatic ACC, and was found to have 38% sensitivity and 100% specificity in detecting primary ACC and metastatic ACC lesions, numbers that were favorable compared with FDG-PET. A third of patients had 123 I-metomidate uptake in all lesions larger than 2 cm [41]. …”

Section: Evaluation and Work-upmentioning

confidence: 99%

Adrenocortical Carcinoma: Modern Management and Evolving Treatment Strategies

McDuffie

Aufforth

2016

Int. J. Endo. Oncol.

View full text Add to dashboard Cite

Adrenocortical carcinoma (ACC) is a rare cancer with a poor prognosis. Unlike many other cancers, there has been little improvement in patient outcome over the past several decades. However, as scientific advancements are made and our understanding of the molecular genetics involved in ACC improve then progress may be achieved in this devastating disease. This review focuses on recent literature published in the field of ACC from 2010 to 2015 with an emphasis on improving diagnosis, staging and treatment for ACC.

show abstract

[123I]Iodometomidate Imaging in Adrenocortical Carcinoma

Abstract: Context

Cited by 43 publications

References 23 publications

European Society of Endocrine Surgeons (ESES) and European Network for the Study of Adrenal Tumours (ENSAT) recommendations for the surgical management of adrenocortical carcinoma

European Society of Endocrine Surgeons (ESES) and European Network for the Study of Adrenal Tumours (ENSAT) recommendations for the surgical management of adrenocortical carcinoma

Targeted Molecular Imaging in Adrenal Disease—An Emerging Role for Metomidate PET-CT

Adrenocortical Carcinoma: Modern Management and Evolving Treatment Strategies

Contact Info

Product

Resources

About